Abstract:OBJECTIVE An important prognostic factor in any form of infection seems to be glucose control in patients with type 2 diabetes. There is no information about the effects of tight glycemic control on coronavirus disease 2019 (COVID-19) outcomes in patients with hyperglycemia. Therefore, we examined the effects of optimal glycemic control in patients with hyperglycemia affected by COVID-19. RESEARCH DESIGN AND METHODS Fifty-nine patients with COVID-19 hospitalized with moderate disease were evaluated. On the basis of admission glycemia >7.77 mmol/L, patients were divided into hyperglycemic and normoglycemic groups. Interleukin 6 (IL-6) and D-dimer levels were evaluated at admission and weekly during hospitalization. The composite end point was severe disease, admission to an intensive care unit, use of mechanical ventilation, or death. RESULTS Thirty-four (57.6%) patients were normoglycemic and 25 (42.4%) were hyperglycemic. In the hyperglycemic group, 7 (28%) and 18 (72%) patients were diagnosed with diabetes already before admission, and 10 (40%) and 15 (60%) were treated without and with insulin infusion, respectively. The mean of glycemia during hospitalization was 10.65 ± 0.84 mmol/L in the no insulin infusion group and 7.69 ± 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization. In a risk-adjusted Cox regression analysis, both patients with hyperglycemia and patients with diabetes had a higher risk of severe disease than those without diabetes and with normoglycemia. Cox regression analysis evidenced that patients with hyperglycemia treated with insulin infusion had a lower risk of severe disease than patients without insulin infusion. CONCLUSIONS Insulin infusion may be an effective method for achieving glycemic targets and improving outcomes in patients with COVID-19.

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?

Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States

Impact of blood glucose control on clinical outcomes in type 2 diabetes patients hospitalized with COVID-19 infection

Glycemic Management in Patients with COVID-19 Admitted to the Intensive Care Unit: Evaluation of Glycemic Control and Drug Therapy

Hyperglycemia is a strong predictor of poor prognosis in COVID-19

Diabetic Patients with COVID-19 Infection Are at Higher Risk of ICU Admission and Poor Short-Term Outcome.

Effects of Glycemic Variability in Critically Ill Patients with Coronavirus Disease 2019: A Retrospective Observational Study

Glycemic and lipid profile of patients with COVID-19: Impact on morbidity and mortality

Impact of COVID-19 Therapy on Hyperglycemia

Admission Hyperglycemia As a Predictor of COVID-19 Pneumonia, Cytokine Release Syndrome Progression, and Clinical Outcomes in a Tertiary Care Hospital

Hyperglycemia and blood glucose deterioration are risk factors for severe COVID‐19 with diabetes: A two‐center cohort study

Long-term outcome of patients with diabetic-range hyperglycemia first detected during admission for COVID-19: A single-center observational study

Thresholds of Glycemia and the Outcomes of COVID-19 Complicated with Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring

Predictors of Poor Glycemic Control and Increased Glucose Variability Among Admitted Moderate to Critical COVID-19 Patients with Type 2 Diabetes Mellitus: A Single Center Cross-Sectional Study

Unmanaged Diabetes and Elevated Blood Glucose Are Poor Prognostic Factors in the Severity and Recovery Time in Predominantly Hispanic Hospitalized COVID-19 Patients

Author Response for "the Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single‐center, Retrospective, Observational Study in Wuhan"

Association of Blood Glucose Level and Prognosis of Inpatients with Coexistent Diabetes and COVID-19

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes

The Management of Blood Glucose Should Be Emphasized in the Treatment of COVID-19

The influence of hypoglycemia and hyperglycemia on the adverse outcome of COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis